Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2027-11-30
Target enrollment:
Participant gender:
Summary
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in
the extra cellular domain of the human epidermal growth factor receptor (EGFR). Nimotuzumab
has been granted approval for use in squamous cell carcinoma of head and neck (SCCHN), glioma
and nasopharyngeal cancer in different countries. This is a multi-center, randomized
controlled trial, with the purpose to evaluate the therapeutic efficacy and safety of
nimotuzumab combined with induction chemotherapy plus chemoradiation and adjuvant therapy in
locoregionally advanced nasopharyngeal carcinoma.
Phase:
N/A
Details
Lead Sponsor:
Fourth Affiliated Hospital of Guangxi Medical University
Collaborators:
Affiliated Hospital of Youjiang Medical University for Nationalities Guilin Medical University, China LiuZhou People's Hospital Nanxishan Hospital of Guangxi Zhuang Autonomous Region People's Hospital of Baise Second Affiliated Hospital of Guangzhou Medical University The First People's Hospital of Qinzhou Wuzhou Red Cross Hospital